Memantine/donepezil

{{Short description|Medication}}

{{Use American English|date=December 2023}}

{{Use dmy dates|date=December 2023}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| type = combo

| image =

| width =

| alt =

| caption =

| component1 = Memantine

| class1 = NMDA receptor antagonist

| component2 = Donepezil

| class2 = Acetylcholinesterase inhibitor

| tradename = Namzaric

| Drugs.com = {{drugs.com|cons|memantine-and-donepezil}}

| MedlinePlus =

| DailyMedID = Memantine and donepezil

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = By mouth

| ATC_prefix = N06

| ATC_suffix = DA52

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Namzaric- memantine hydrochloride and donepezil hydrochloride capsule; Namzaric- memantine hydrochloride and donepezil hydrochloride kit | website=DailyMed | date=22 January 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90fedc32-19e5-480c-afc6-f35a5cf4b9aa | access-date=22 December 2023 | archive-date=20 January 2022 | archive-url=https://web.archive.org/web/20220120050522/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90fedc32-19e5-480c-afc6-f35a5cf4b9aa | url-status=live }}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status = Rx-only{{cite web | title=Periodic safety update report single assessment donepezil / memantine | website=European Medicines Agency | date=7 March 2024 | url=https://www.ema.europa.eu/en/medicines/psusa/psusa-00011039-202307 | access-date=2 May 2024}}

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D11387

| ChEBI =

| ChEMBL =

| synonyms =

}}

Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. It contains memantine hydrochloride (it acts as an NMDA receptor antagonist, among various other types of targets like 5-HT3 receptor, Nicotinic acetylcholine receptor, and Sigma-1 receptor) and donepezil hydrochloride, which is an acetylcholinesterase inhibitor. It is taken by mouth.

Memantine/donepezil was approved for medical use in the United States in 2014.{{cite web | title=Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules | website=U.S. Food and Drug Administration (FDA) | date=13 May 2015 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206439Orig1s000TOC.cfm | access-date=22 December 2023 | archive-date=22 December 2023 | archive-url=https://web.archive.org/web/20231222203410/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206439Orig1s000TOC.cfm | url-status=live }}